Biomedical Engineering Reference
In-Depth Information
chose.25.µg/ml.concentration.of.docetaxel.is.that.the.IC50.of.the.MCF-7.breast.cancer.cells.
has.been.found.to.be.13.2.µM,.i.e.,.10.7.µg/ml.(the.molecular.weight.of.docetaxel.is.808)..
From.Figure 8.7,.the.following.conclusions.can.be.obtained.
The. viability. for. both. cell. lines. was. decreased. with. an. increase. of. the. incuba-
tion. time,. which. means. the. longer. the. culture. time,. the. higher. the. cytotoxicity.. This. is.
straightforward.
From.the.irst.column.of.each.group.for.Blank-NP20,.it.can.be.found.from.Figure 8.7A.for.
MCF-7.cells.that.the.viabilities.for.placebo.PLA-TPGS/TPGS-COOH.NPs.without.trastu-
zumab.functionalization.were.96.1.±.2.6%,.95.5.±.3.8%,.and.94.8.±.5.2%.after.24,.48,.and.72.
h.incubation,.respectively..In.comparison,.similar.results.can.be.found.in.Figure 8.7B;.that.
is,.the.viabilities.of.SK-BR-3.cells.for.placebo.PLA-TPGS/TPGS-COOH.NPs.without.tras-
tuzumab.functionalization.were.98.4.±.4.0%,.95.5.±.5.7%,.and.95.7.±.4.2%.after.24,.48,.and.
72.h.incubation,.respectively..This.means.that.the.cytotoxicities.of.the.placebo.PLA-TPGS/
TPGS-COOH.NPs.have.high.biocompatibility.with.fractional.cytotoxicity.
The. second. column. of. each. group. in. Figure 8.7A. and. B. stands. for. the. cell. viabil-
ity. of. placebo. PLA-TPGS/TPGS-COOH. NPs. with. trastuzumab. surface. modiication.
(Blank-NP20-HER).. In. Figure 8.7A,. the. viabilities. of. MCF-7. cells. are. 90.3. ±. 3.3%,. 85.3. ±.
4.8%,.and.78.7.±.5.2%.after.24,.48,.and.72.h.cell.culture,.respectively..In.Figure 8.7B,.how-
ever,.the.viabilities.of.SK-BR-3.cells.are.slightly.lower:.88.2.±.5.1%,.80.3.±.6.6%,.and.75.3.±.
4.3%.for.24,.48,.and.72.h,.respectively..The.results.clearly.show.the.targeting.effects.of.the.
trastuzumab-functionalized.NPs.for.the.breast.cancer.cells.of.high.HER2.overexpression.
The.third.column.of.every.group.in.Figure 8.7.shows.the.viabilities.of.the.two.breast.can-
cer.cell.lives.after.24,.48,.and.72.h.treatment.with.Taxotere,.which.are.56.9.±.2.6%,.51.3.±.4.3%,.
and.43.2.±.3.6%.for.MCF-7.cells.and.61.3.±.1.9%,.57.8.±.2.1%,.and.41.4.±.1.4%.for.SK-BR-3.cells,.
respectively..This.means.that.Taxotere.may.be.more.effective.for.MCF-7.breast.cancer.cells.
than.for.SK-BR-3.breast.cancer.cells.in.a.short.time.(24.and.48.h),.and.the.effect.may.become.
inverse.in.a.longer.time.(72.h)..In.comparison,.the.in.vitro.viabilities.shown.in.the.fourth.
column.of.each.group.in.Figure 8.7A.and.B.are.55.8.±.3.1%,.43.2.±.3.0%,.and.15.6.±.3.4%.for.
MCF-7.cells.and.62.7.±.2.8%,.51.9.±.6.1%,.and.16.4.±.3.2%.for.SK-BR-3.cells.after.24,.48,.and.72.
h.treatment,.respectively..This.means.that.evaluated.by.cellular.mortality,.the.NP.formula-
tion.has.an.in.vitro.therapeutic.effect.(1.025-fold.for.MCF-7.cells.and.0.964-fold.for.SK-BR-3.
cells).comparable.to.that.of.Taxotere.after.24.h.cell.culture..However,.the.NP.formulation.of.
docetaxel.would.be.1.166-.and.1.486-fold.for.MCF-7.cells.and.1.140-.and.1.427-fold.for.SK-BR-3.
cells,.and.thus.more.effective.than.that.of.Taxotere,.after.48.and.72.h.treatment,.respectively..
This.may.be.attributed.to.the.sustainable.drug.release.manner.of.the.NP.formulation.
The.ifth.column.at.the.right.of.every.group.in.Figure 8.7A.and.B.shows.the.viabilities.of.the.
MCF-7.and.SK-BR-3.breast.cancer.cell.lines.after.24,.48,.and.72.h.treatment.with.NP20-HER,.
which.are.46.3.±.2.7%,.31.0.±.3.2%,.and.9.4.±.3.1%.for.MCF-7.cells.and.36.7.±.1.3%,.9.2.±.2.0%,.
and.5.9.±.2.5%.for.SK-BR-3.cells,.respectively..It.can.thus.be.concluded.that,.judged.by.cellular.
mortality,.the.trastuzumab-functionalized.NP.formulation.can.be.1.215-,.1.215-,.and.1.073-fold.
for.MCF-7.cells.and.1.697-,.1.886-,.and.1.126-fold.for.SK-BR-3.cells.more.effective.than.the.NP.
formulation.with.no.trastuzumab.functionalization.after.24,.48,.and.72.h.treatment,.respec-
tively..The.targeting.effects.of.trastuzumab.functionalization.thus.showed.39.7,.55.2,.and.4.9%.
higher.cancer.cell.mortality.for.SK-BR-3.cells.of.high.HER2.overexpression.than.for.MCF-7.
cells.of.moderate.HER2.overexpression.after.24,.48,.and.72.h.treatment,.respectively.
Combined.with.the.advantages.of.the.PLA-TPGS/TPGS-COOH.NP.formulation.and.the.
trastuzumab. functionalization,. the. trastuzumab-functionalized. NP. formulation. can. be.
1.245-,.1.417-,.and.1.594-fold.for.MCF-7.cells.and.1.635-,.2.150-,.and.1.606-fold.for.SK-BR-3.
cells.more.effective.than.Taxotere.after.24,.48,.and.72.h.treatment,.respectively.
